Articles with public access mandates - Gerhardt AttardLearn more
Not available anywhere: 30
Review
Evolution of androgen receptor targeted therapy for advanced prostate cancer
YNS Wong, R Ferraldeschi, G Attard, J De Bono
Nature reviews Clinical oncology 11 (6), 365-376, 2014
Mandates: Cancer Research UK, National Institute for Health Research, UK, Prostate …
Review
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway
G Attard, J Richards, JS de Bono
Clinical cancer research 17 (7), 1649-1657, 2011
Mandates: Cancer Research UK
Review
Sequencing of agents in castration-resistant prostate cancer
D Lorente, J Mateo, R Perez-Lopez, JS de Bono, G Attard
The Lancet Oncology 16 (6), e279-e292, 2015
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Review
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents
CJ Pezaro, AG Omlin, A Altavilla, D Lorente, R Ferraldeschi, D Bianchini, ...
European urology 66 (3), 459-465, 2014
Mandates: Cancer Research UK, National Institute for Health Research, UK, Prostate …
Review
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
A Omlin, C Pezaro, D Mukherji, AM Cassidy, S Sandhu, D Bianchini, ...
European urology 64 (2), 300-306, 2013
Mandates: Cancer Research UK, Prostate Cancer UK
Review
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised …
F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, ...
The Lancet Oncology 22 (11), 1541-1559, 2021
Mandates: US National Institutes of Health
Review
Integration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer
S Jhavar, D Brewer, S Edwards, Z Kote‐Jarai, G Attard, J Clark, P Flohr, ...
BJU international 103 (9), 1256-1269, 2009
Mandates: Cancer Research UK
Review
The CT flare response of metastatic bone disease in prostate cancer
C Messiou, G Cook, AHM Reid, G Attard, D Dearnaley, JS de Bono, ...
Acta Radiologica 52 (5), 557-561, 2011
Mandates: Cancer Research UK
Review
Abiraterone acetate is well tolerated without concomitant use of corticosteroids
G Attard, AHM Reid, JS de Bono
Journal of Clinical Oncology 28 (29), e560-e561, 2010
Mandates: Cancer Research UK
Review
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone
A Pia, F Vignani, G Attard, M Tucci, P Bironzo, G Scagliotti, W Arlt, ...
Cancer treatment reviews 39 (8), 966-973, 2013
Mandates: Cancer Research UK, UK Medical Research Council
Review
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
A Eichholz, R Ferraldeschi, G Attard, JS de Bono
Molecular and cellular endocrinology 360 (1-2), 68-75, 2012
Mandates: Cancer Research UK
Review
Sarcomatoid carcinoma of the prostate: ERG fluorescence in‐situ hybridization confirms epithelial origin
DN Rodrigues, S Hazell, S Miranda, M Crespo, C Fisher, JS de Bono, ...
Histopathology 66 (6), 898-901, 2015
Mandates: Cancer Research UK, National Institute for Health Research, UK, Prostate …
Review
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone
P Ravi, J Mateo, D Lorente, Z Zafeiriou, A Altavilla, R Ferraldeschi, ...
European urology 66 (1), 8-11, 2014
Mandates: Cancer Research UK, National Institute for Health Research, UK, Prostate …
Review
Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity
G Attard, C Jameson, J Moreira, P Flohr, C Parker, D Dearnaley, ...
Journal of clinical pathology 62 (4), 373-376, 2009
Mandates: Cancer Research UK
Review
Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative
G Attard, M Crespo, AC Lim, L Pope, A Zivi, JS de Bono
Clinical Cancer Research 17 (9), 3048-3049, 2011
Mandates: Cancer Research UK
Review
The development of abiraterone acetate for castration-resistant prostate cancer
E Grist, G Attard
Urologic Oncology: Seminars and Original Investigations 33 (6), 289-294, 2015
Mandates: Cancer Research UK, National Institute for Health Research, UK, Prostate …
Review
Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer
A Chiin Lim, G Attard
Current Drug Targets 14 (4), 408-419, 2013
Mandates: Cancer Research UK, Wellcome Trust
Review
Redefining the therapeutic landscape for CRPC
C Pezaro, G Attard
Nature reviews Urology 9 (2), 63-64, 2012
Mandates: Cancer Research UK
Review
Targeting extra-gonadal androgens in castration-resistant prostate cancer
E Grist, JS de Bono, G Attard
The Journal of steroid biochemistry and molecular biology 145, 157-163, 2015
Mandates: Cancer Research UK, Prostate Cancer UK
Review
Pharmacokinetics, safety, and antitumor effect of apalutamide with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: phase Ib study
EM Posadas, KN Chi, R de Wit, MJA de Jonge, G Attard, TW Friedlander, ...
Clinical Cancer Research 26 (14), 3517-3524, 2020
Mandates: Cancer Research UK
Publication and funding information is determined automatically by a computer program